L8 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:872680 CAPLUS Full-text
DN 141:343501
TI Use of an IBAT inhibitor for the treatment of prophylaxis of constipation
IN Abrahamsson, Hasse Roland; Gillberg, Per-Goran
PA Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089350	A1	20041021	WO 2004-GB1396	20040401
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004228731	A1	20041021	AU 2004-228731	20040401
	CA 2520109	AA	20041021	CA 2004-2520109	20040401
	EP 1610770	A1	20060104	EP 2004-725081	20040401
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004008858	A	20060411	BR 2004-8858	20040401
	CN 1771027	A	20060510	CN 2004-80009415	20040401
	NO 2005004369	A	20051115	NO 2005-4369	20050921
PRAI	GB 2003-7918	A	20030405		
	WO 2004-GB1396	A	20040401		

AB The use of an ileal bile acid transport (IBAT) inhibitor in the treatment and/or prophylaxis of constipation, in a warm-blooded animal, such as man is described.

IT **501692-15-5 501692-16-6 501692-17-7**
501692-21-3 501692-27-9 501692-28-0
501692-31-5 501692-40-6 501692-41-7
501692-43-9 501692-44-0 501692-46-2
501692-50-8 549501-81-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of an ileal bile acid transport inhibitor for the treatment of prophylaxis of constipation)

RN 501692-15-5 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-16-6 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-17-7 CAPLUS
CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-21-3 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-27-9 CAPLUS
CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-28-0 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-31-5 CAPLUS
CN Benzeneacetic acid, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-40-6 CAPLUS
CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-41-7 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-43-9 CAPLUS
CN L-Norvaline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-44-0 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-46-2 CAPLUS
CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-50-8 CAPLUS
CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-(2S)-2-aminobutanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-81-7 CAPLUS
CN Ethanesulfonic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:546469 CAPLUS Full-text
DN 141:106266
TI Preparation of phenylpropanoic acids derivatives as selective PPARα modulators
IN Lindstedt Alstermark, Eva-Lotte; Olsson, Anna Christina; Li, Lanna; Aurell, Carl-Johan; Minidis, Anna; Yousefi-Salakdeh, Esmail; Dahlstrom, Mikael Ulf Johan
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056748	A1	20040708	WO 2003-GB5602	20031219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2508851	AA	20040708	CA 2003-2508851	20031219
	AU 2003290309	A1	20040714	AU 2003-290309	20031219
	US 2005131068	A1	20050616	US 2003-499893	20031219
	EP 1572626	A1	20050914	EP 2003-782668	20031219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003017458	A	20051116	BR 2003-17458	20031219
	CN 1753862	A	20060329	CN 2003-80109895	20031219
	JP 2006511572	T2	20060406	JP 2004-561668	20031219
	US 2005282822	A1	20051222	US 2004-26806	20041230
	NO 2005002914	A	20050719	NO 2005-2914	20050615
	JP 2006045240	A2	20060216	JP 2005-253346	20050901
PRAI	GB 2002-29931	A	20021221		
	SE 2001-4334	A	20011219		
	WO 2002-GB5738	W	20021218		
	WO 2002-GB5744	A	20021218		
	GB 2003-14079	A	20030618		
	JP 2004-561668	A3	20031219		
	WO 2003-GB305602	A	20031219		
	WO 2003-GB5602	W	20031219		
	WO 2004-EP6597	A	20040617		
	US 2005-499261	A2	20050304		

OS CASREACT 141:106266; MARPAT 141:106266
GI



I

AB Title compds. I [R1 = Cl, CF3, CF3O; R2 = H, F; R3 = alkyl] and their pharmaceutically acceptable salts, prodrugs were prepared For example, amidation of N-butyl-N-[2-fluoro-4-(trifluoromethyl)benzyl]amine, e.g., prepared from Et (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate in 3 steps, and {4-[(2S)-2,3-diethoxy-3-oxopropyl]phenoxy}acetic acid, followed by hydrolysis afforded compound (S)-I [R1 = CF3; R2 = F; R3 = butyl] in 72% yield. Compds. I have EC50 values <0.1 μmol/L for PPARα, e.g., the EC50 value of compound (S)-I [R1 = CF3; R2 = F; R3 = butyl] was 0.001 μmol/L. Of notes, compds. I exhibit improved metabolic stability (in vitro), promising toxicol. profile (no data provided) and particular compds. have the ratio of the EC50(PPARγ):EC50(PPARγ) <150:1. Compds. I are claimed useful for the treatment of hypertension, diabetes, etc.

IT **501692-15-5 501692-16-6 501692-17-7 501692-21-3 501692-27-9 501692-28-0 501692-40-6 501692-41-7 501692-43-9 501692-44-0 501692-46-2 501692-50-8 549501-81-7 549501-82-8 549501-83-9 549501-84-0**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicaments with; preparation of phenylpropanoic acids derivs. as selective
PPARα modulators for treatment of dyslipidemia)

RN 501692-15-5 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-16-6 CAPLUS

CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-17-7 CAPLUS
CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-21-3 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-27-9 CAPLUS
CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-28-0 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-40-6 CAPLUS
CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-41-7 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-43-9 CAPLUS
CN L-Norvaline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-44-0 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-46-2 CAPLUS
CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-50-8 CAPLUS
CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-(2S)-2-aminobutanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-81-7 CAPLUS
CN Ethanesulfonic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-82-8 CAPLUS
CN Benzeneacetamide, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-N-[(1S,2R)-2-(3,4-dihydroxyphenyl)-2-hydroxy-1-methylethyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-83-9 CAPLUS
CN D-Glucitol, 1-deoxy-1-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-84-0 CAPLUS
CN D-Glucitol, 1-deoxy-1-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

Appl's

L8 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:875267 CAPLUS Full-text
DN 139:350761
TI Preparation of 1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepines as ileal bile acid transport inhibitors for treatment of hyperlipidemia
IN Starke, Ingemar; Dahlstrom, Mikael Ulf Johan; Nordberg, Mats Peter; Alenfalk, Suzanne; Wallberg, Andreas Christer; Bostrom, Stig Jonas
PA Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003091232	A2	20031106	WO 2003-GB1742	20030423
	WO 2003091232	A3	20031224		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2483155	AA	20031106	CA 2003-2483155	20030423
	AU 2003226565	A1	20031110	AU 2003-226565	20030423
	EP 1501813	A2	20050202	EP 2003-747171	20030423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009493	A	20050209	BR 2003-9493	20030423
	US 2005143368	A1	20050630	US 2003-511984	20030423
	CN 1662514	A	20050831	CN 2003-814359	20030423
	JP 2005531537	T2	20051020	JP 2003-587792	20030423
	NO 2004004597	A	20041027	NO 2004-4597	20041025
PRAI	GB 2002-9467	A	20020425		
	WO 2003-GB1742	W	20030423		

OS MARPAT 139:350761
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein Rv = H, alkyl; R1 = H, alkyl when R2 = alkyl; R2 = H, alkyl when R1 = alkyl; Rx, Ry = independently H, OH and derivs., NH2 and derivs., SH, alkyl, alkylS(O)a; a = 0-2; Rz = halo, NO2, CN, OH and derivs., NH2 and derivs., carboxy, carbamoyl, mercapto, sulphamoyl, alk(en/yn)yl, etc.; n = 0-5; one of R4 and R5 = -X-Y-C(O)-N(R8)-(CAR9R10); R3 and R6 and the other of R4 and R5 = independently H, halo, NO2, CN, OH and derivs., NH2 and derivs., SH, sulphamoyl and derivs., (un)substituted alk(en/yn)yl, etc.; X = O, NH and derivs., CH2 and derivs., S(O)b; b = 0-2; A = C-(un)substituted (hetero)aryl; Y = (CHR7)q; R7 = H, (un)substituted alkyl, carbocyclyl, C- or N-(un)substituted heterocyclyl; q = 1-3; R8 = H, alkyl; R9 = H, alkyl; R10 = H, halo, NO2, NH2 and derivs., OH and derivs., CN, SH, (un)substituted alk(en/yn)yl, carbocyclyl, C- or N-(un)substituted heterocyclyl, etc.; their

stereoisomers, geometric isomers, tautomers, pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs] were prepared as ileal bile acid transport (IBAT) inhibitors (no data) for treatment of hyperlipidemia (no data). For example, II was prepared, in 59% yield, by condensation of benzothiadiazepine III (preparation given) with (D)-glucamine in the presence of N-methylmorpholine/TBTU/DMF.

IT **549501-83-9P**, 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-N-[(R)-[α-[N-[2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl]carbamoyl]-4-hydroxybenzyl]carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine **549501-84-0P**, 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-[(R)-α-[N-[2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl]carbamoyl]benzyl]carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine **618908-34-2P**, 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-(R)-α-[N-[1-(R)-2-(S)-1-hydroxy-1-(3,4-dihydroxyphenyl)prop-2-yl]carbamoyl]benzyl]carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine **618908-35-3P**, 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-[(S)-α-[N-[1-(R)-2-(S)-1-hydroxy-1-(3,4-dihydroxyphenyl)prop-2-yl]carbamoyl]benzyl]carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine **618908-36-4P**, 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-[(R)-α-[N-[2-(S)-[N-(carbamoylmethyl)carbamoyl]pyrrolidin-1-ylcarbonylmethyl]carbamoyl]benzyl]carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine **618908-37-5P**, 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-[(R)-α-[N-[2-(3,4,5-trihydroxyphenyl)ethyl]carbamoyl]benzyl]carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine **618908-38-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ileal bile acid transport inhibitor; preparation of benzothiadiazepines as ileal bile acid transport inhibitors for treatment of hyperlipidemia)

RN 549501-83-9 CAPLUS

CN D-Glucitol, 1-deoxy-1-[[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-84-0 CAPLUS

CN D-Glucitol, 1-deoxy-1-[[(2R)-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 618908-34-2 CAPLUS
CN Benzeneacetamide, N-[(1R,2S)-2-amino-2-(3,4-dihydroxyphenyl)-1-hydroxyethyl]-α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 618908-35-3 CAPLUS
CN Benzeneacetamide, N-[(1R,2S)-2-amino-2-(3,4-dihydroxyphenyl)-1-hydroxyethyl]-α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 618908-36-4 CAPLUS
CN Glycinamide, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycylglycyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH_2

RN 618908-37-5 CAPLUS

CN Benzeneacetamide, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-N-[2-(3,4,5-trihydroxyphenyl)ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 618908-38-6 CAPLUS

CN D-Galactose, 6-deoxy-6-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501692-31-5P**, 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-((R)-α-carboxy-4-hydroxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine **501692-39-3P**, 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-((R)-α-carboxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine **501692-67-7P**, 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-[(R)-α-(tert-butoxycarbonyl)benzyl]carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine **618908-39-7P**, 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-((R)-α-tert-butoxycarbonyl-4-hydroxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzothiadiazepines as ileal bile acid transport inhibitors for treatment of hyperlipidemia)

RN 501692-31-5 CAPLUS

CN Benzeneacetic acid, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-39-3 CAPLUS

CN Benzeneacetic acid, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-67-7 CAPLUS

CN Benzeneacetic acid, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-, 1,1-dimethylethyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 618908-39-7 CAPLUS

CN Benzeneacetic acid, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, 1,1-dimethylethyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:491169 CAPLUS Full-text
DN 139:69054
TI Preparation of substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)
IN Alstermark Lindstedt, Eva-Lotte; Olsson, Anna Christina; Li, Lanna
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051822	A1	20030626	WO 2002-GB5744	20021218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2469302	AA	20030626	CA 2002-2469302	20021218
	AU 2002352427	A1	20030630	AU 2002-352427	20021218
	EP 1458672	A1	20040922	EP 2002-788145	20021218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002014986	A	20041214	BR 2002-14986	20021218
	CN 1620422	A	20050525	CN 2002-828123	20021218
	CN 1620423	A	20050525	CN 2002-828155	20021218
	US 2005113362	A1	20050526	US 2003-499378	20021218
	JP 2005526704	T2	20050908	JP 2003-552710	20021218
	ZA 2004004657	A	20050829	ZA 2004-4657	20040611
	NO 2004003164	A	20040716	NO 2004-3164	20040716
	US 2005282822	A1	20051222	US 2004-26806	20041230
	JP 2005336209	A2	20051208	JP 2005-235794	20050816
PRAI	SE 2001-4334	A	20011219		
	JP 2003-552709	A3	20021218		
	WO 2002-GB5738	W	20021218		
	WO 2002-GB5744	W	20021218		
	GB 2002-29931	A	20021221		
	GB 2003-14079	A	20030618		
	WO 2003-GB305602	A	20031219		
	WO 2004-EP6597	A	20040617		
	US 2005-499261	A2	20050304		

OS MARPAT 139:69054
GI



I

AB The present invention provides the S enantiomer of a compound of formula (I) (wherein R1 represents 2,4-difluorophenyl or cyclohexyl) as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, processes for preparing such compds., their the utility in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use, and pharmaceutical compns. containing them. Thus, to a solution of [4-((2S)-2,3-diethoxy-3-oxopropyl)phenoxy]acetic acid (0.108 g) 3.6 mL CH2Cl2 were added N-(cyclohexylmethyl)-N-heptylamine hydrochloride (0.090 g) and DMAP (0.098 g) followed by 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (0.070 g) and the reaction mixture was stirred at room temperature overnight to give, after workup and silica gel chromatog., Et (2S)-3-[4-[2-[(cyclohexylmethyl)(heptyl)amino]-2- oxoethoxy]phenyl]-2-ethoxypropanoate which (0.031 g) was saponified with LiOH in aqueous THF at room temperature overnight and acidified with aqueous 2 M HCl to give (2S)-3-[4-[2-[(cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy]phenyl]-2- ethoxypropanoic acid. The compds. I had EC50 of less than 0.5 μmol/L for PPARα and preferred compds. have EC50 of less than 0.05 μmol/L for PPARα. They were more potent with respect to PPARα than with respect to PPARγ.

IT **501692-15-5 501692-16-6 501692-17-7**
501692-21-3 501692-27-9 501692-28-0
501692-40-6 501692-41-7 501692-43-9
501692-44-0 501692-46-2 501692-50-8
549501-81-7 549501-82-8 549501-83-9
549501-84-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ideal bile acid transport system (IBAT) inhibitor, drug containing; preparation
of substituted phenylpropionic acid derivs. as agonists to human peroxisome proliferator-activated receptor alpha (PPAR) for treating lipid disorders)

RN 501692-15-5 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-16-6 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-17-7 CAPLUS
CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-21-3 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-27-9 CAPLUS
CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-28-0 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-40-6 CAPLUS
CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-41-7 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-43-9 CAPLUS
CN L-Norvaline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-44-0 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-46-2 CAPLUS
CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-50-8 CAPLUS
CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-(2S)-2-aminobutanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-81-7 CAPLUS
CN Ethanesulfonic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-82-8 CAPLUS
CN Benzeneacetamide, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-N-[(1S,2R)-2-(3,4-dihydroxyphenyl)-2-hydroxy-1-methylethyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-83-9 CAPLUS
CN D-Glucitol, 1-deoxy-1-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-84-0 CAPLUS
CN D-Glucitol, 1-deoxy-1-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:491168 CAPLUS Full-text
DN 139:69049
TI Preparation of substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)
IN Alstermark Lindstedt, Eva-Lotte; Olsson, Anna Christina; Li, Lanna
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051821	A1	20030626	WO 2002-GB5738	20021218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2470491	AA	20030626	CA 2002-2470491	20021218
	AU 2002366315	A1	20030630	AU 2002-366315	20021218
	EP 1458673	A1	20040922	EP 2002-804964	20021218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002014988	A	20041214	BR 2002-14988	20021218
	CN 1620422	A	20050525	CN 2002-828123	20021218
	CN 1620423	A	20050525	CN 2002-828155	20021218
	US 2005171204	A1	20050804	US 2003-499261	20021218
	JP 2005526011	T2	20050902	JP 2003-552709	20021218
	ZA 2004004657	A	20050829	ZA 2004-4657	20040611
	NO 2004003023	A	20040715	NO 2004-3023	20040715
	US 2005282822	A1	20051222	US 2004-26806	20041230
	JP 2005336209	A2	20051208	JP 2005-235794	20050816
PRAI	SE 2001-4334	A	20011219		
	JP 2003-552709	A3	20021218		
	WO 2002-GB5738	W	20021218		
	WO 2002-GB5744	A	20021218		
	GB 2002-29931	A	20021221		
	GB 2003-14079	A	20030618		
	WO 2003-GB305602	A	20031219		
	WO 2004-EP6597	A	20040617		
	US 2005-499261	A2	20050304		

OS MARPAT 139:69049
GI



I

AB The S enantiomer of I, n = 1 or 2, (C6H13 = hexyl) as well as their pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs are synthesized using various solvents and in presence of charcoal-supported palladium catalyst. The utility of these compds. in clin. conditions such as lipid disorders (dyslipidemias) whether or not associated with insulin resistance and therapeutic and other pharmaceutical activities is also investigated. For example, (2S)-3-(4{2-[benzyl(hexyl)amino]-2-oxoethoxy}phenyl)2-ethoxypropionic acid was prepared in 58% yield via reaction of (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate and benzyl bromoacetate.

IT **501692-15-5P 501692-16-6P 501692-17-7P**
501692-21-3P 501692-27-9P 501692-28-0P
501692-40-6P 501692-41-7P 501692-43-9P
501692-44-0P 501692-46-2P 501692-50-8P
549501-81-7P 549501-82-8P 549501-83-9P
549501-84-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of enantiomeric substituted phenylpropionic acid derivs. as agonists to human peroxisome proliferator-activated receptor)

RN 501692-15-5 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-16-6 CAPLUS

CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-17-7 CAPLUS

CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-

methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-21-3 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-27-9 CAPLUS
CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-28-0 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-40-6 CAPLUS
CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-41-7 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-43-9 CAPLUS
CN L-Norvaline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-44-0 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-46-2 CAPLUS
CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-50-8 CAPLUS
CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-

dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-(2S)-2-aminobutanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-81-7 CAPLUS

CN Ethanesulfonic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-82-8 CAPLUS

CN Benzeneacetamide, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-N-[(1S,2R)-2-(3,4-dihydroxyphenyl)-2-hydroxy-1-methylethyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-83-9 CAPLUS
CN D-Glucitol, 1-deoxy-1-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549501-84-0 CAPLUS
CN D-Glucitol, 1-deoxy-1-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/478,470

DP

L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:221521 CAPLUS Full-text
DN 138:238208
TI Preparation of benzothiazepine and benzothiadiazepine derivatives for potential use as ileal bile acid transport inhibitors for the treatment of hyperlipidemia
IN Starke, Ingemar; Dahlstrom, Mikael Ulf Johan; Blomberg, David; Alenfalk, Suzanne; Skjaret, Tore; Lemurell, Malin
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003022286	A1	20030320	WO 2002-GB4033	20020905
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2459449	AA	20030320	CA 2002-2459449	20020905
	EP 1427423	A1	20040616	EP 2002-765013	20020905
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2004521961	T2	20040722	JP 2003-526415	20020905
	JP 3616635	B2	20050202		
	BR 2002012346	A	20040810	BR 2002-12346	20020905
	CN 1582151	A	20050216	CN 2002-822113	20020905
	NZ 531796	A	20051028	NZ 2002-531796	20020905
	JP 2004210794	A2	20040729	JP 2004-38919	20040216
	NO 2004000948	A	20040304	NO 2004-948	20040304
	ZA 2004001798	A	20050131	ZA 2004-1798	20040304
	US 2005038009	A1	20050217	US 2004-488870	20041007
PRAI	GB 2001-21768	A	20010908		
	GB 2002-9463	A	20020425		
	JP 2003-526415	A3	20020905		
	WO 2002-GB4033	W	20020905		

OS MARPAT 138:238208
GI



I

AB Benzothiazepines I, wherein R1 and R2 are selected from hydrogen, alkyl, alkenyl, and the other is selected from alkyl, alkenyl; R3 and R6 and the other of R4 and R5 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkanoyloxy, N-(alkyl)amino, N,N-(alkyl)2amino, alkanoylamino, N-(alkyl)carbamoyl, N,N- (alkyl)2carbamoyl, alkyl-S(O)a wherein a is 0 to 2, alkoxycarbonyl, N-(alkyl)sulphamoyl and N,N-(alkyl)2sulphamoyl; wherein R3 and R6 and the other of R4 and R5 may be optionally substituted on carbon; R7 and R8 are independently H, OH, amino, mercapto, alkyl, alkoxy, N-(alkyl)amino,N,N- (alkyl)amino, alkyl-S(O)a wherein a is 0-2; R9 is H, alkyl; R10 is (Rz)v; Rz is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkanoyloxy, N-(alkyl)amino, N,N-(alkyl)2amino, alkanoylamino, N-(alkyl)carbamoyl, N,N-(alkyl)2carbamoyl, alkyl-S(O)a wherein a is 0 to 2, alkoxycarbonyl, N-(alkyl)sulphamoyl and N,N-(alkyl)2sulphamoyl; v is 0-5; M is N, CH; variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their potential use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidemia. Processes for their manufacture and pharmaceutical compns. containing them are also described. Thus, 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5- tetrahydro-1,2,5-benzothiadiazepine was prepared and tested as ileal bile acid transport inhibitor and for the treatment of hyperlipidemia (no data).

IT **501692-23-5P 501692-24-6P 501692-31-5P**
501692-39-3P 501692-42-8P 501692-45-1P
501692-47-3P 501692-65-5P 501692-66-6P
501692-67-7P 501692-68-8P 501692-70-2P
501692-71-3P 501692-78-0P 501692-79-1P
501692-80-4P 501692-81-5P 501692-86-0P
501692-89-3P 501692-91-7P 501692-92-8P
501692-93-9P 501692-94-0P 501692-95-1P
501692-97-3P 501692-98-4P 501692-99-5P
501693-00-1P 501693-01-2P 501693-04-5P
501693-05-6P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzothiazepine and benzothiadiazepine derivs. for potential
use as ileal bile acid transport inhibitors for the treatment of hyperlipidemia)

RN 501692-23-5 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-24-6 CAPLUS

CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-, 1,1-dimethylethyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● NH_3

RN 501692-31-5 CAPLUS

CN Benzeneacetic acid, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-39-3 CAPLUS

CN Benzeneacetic acid, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-42-8 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-45-1 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-47-3 CAPLUS
CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-S-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-65-5 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methyl-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-66-6 CAPLUS
CN L-Ornithine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N5-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 501692-67-7 CAPLUS

CN Benzeneacetic acid, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-, 1,1-dimethylethyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-68-8 CAPLUS

CN L-Proline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-70-2 CAPLUS
CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-71-3 CAPLUS
CN Butanoic acid, 3-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-2-hydroxy-, 1,1-dimethylethyl ester, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-78-0 CAPLUS
CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-(2S)-2-aminobutanoyl-O-(1,1-dimethylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-79-1 CAPLUS

CN Leucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-4-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-80-4 CAPLUS
CN L-Proline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-81-5 CAPLUS
CN 2-Azetidinecarboxylic acid, 1-[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-86-0 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-L-alanyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-89-3 CAPLUS
CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-O-(1,1-dimethylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-91-7 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-92-8 CAPLUS
CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-93-9 CAPLUS
CN L-Asparagine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-94-0 CAPLUS
CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-95-1 CAPLUS
CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-, 1,1-dimethylethyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● NH_3

RN 501692-97-3 CAPLUS
CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-O-(1,1-dimethylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-98-4 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, 1,1-dimethylethyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● NH_3

RN 501692-99-5 CAPLUS
CN L-Leucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, 1,1-dimethylethyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501693-00-1 CAPLUS

CN L-Isoleucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501693-01-2 CAPLUS

CN Benzeneacetic acid, α-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-4-hydroxy-, 1,1-dimethylethyl ester, monoammonium salt, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501693-04-5 CAPLUS

CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-O-(1,1-dimethylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501693-05-6 CAPLUS
CN L-Norvaline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501692-11-1P 501692-12-2P 501692-13-3P**
501692-14-4P 501692-15-5P 501692-16-6P
501692-17-7P 501692-18-8P 501692-19-9P
501692-20-2P 501692-21-3P 501692-25-7P
501692-26-8P 501692-27-9P 501692-28-0P
501692-29-1P 501692-30-4P 501692-33-7P
501692-34-8P 501692-35-9P 501692-36-0P
501692-37-1P 501692-38-2P 501692-40-6P
501692-41-7P 501692-43-9P 501692-44-0P
501692-46-2P 501692-48-4P 501692-49-5P
501692-50-8P 501692-51-9P 501692-52-0P
501692-53-1P 501692-54-2P 501692-55-3P
501692-56-4P 501692-57-5P 501692-58-6P
501692-90-6P 501692-96-2P 501693-06-7P
501693-07-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of benzothiazepine and benzothiadiazepine derivs. for potential
use as ileal bile acid transport inhibitors for the treatment of hyperlipidemia)

RN 501692-11-1 CAPLUS

CN Glycine, (2R)-N-[[[7-bromo-3,3-dibutyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-12-2 CAPLUS

CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-13-3 CAPLUS

CN Ethanesulfonic acid, 2-[[(2R)-[[[(7-bromo-3,3-dibutyl-2,3,4,5-tetrahydro-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-14-4 CAPLUS
CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-15-5 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-16-6 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-17-7 CAPLUS
CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-18-8 CAPLUS
CN L-Asparagine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-19-9 CAPLUS
CN Ethanesulfonic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-20-2 CAPLUS
CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-21-3 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-25-7 CAPLUS
CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-26-8 CAPLUS
CN Ethanesulfonic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, monoammonium salt (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 501692-27-9 CAPLUS
CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-28-0 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-29-1 CAPLUS
CN L-Leucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-30-4 CAPLUS
CN L-Isoleucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-33-7 CAPLUS
CN L-Ornithine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-34-8 CAPLUS
CN L-Ornithine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N5-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 501692-35-9 CAPLUS
CN L-Proline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-36-0 CAPLUS
CN Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-37-1 CAPLUS
CN Butanoic acid, 3-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-2-hydroxy-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-38-2 CAPLUS
CN Methanesulfonic acid, [[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]amino]-, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● NH_3

RN 501692-40-6 CAPLUS
CN L-Threonine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-41-7 CAPLUS
CN L-Valine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-43-9 CAPLUS
CN L-Norvaline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-44-0 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-46-2 CAPLUS
CN L-Cysteine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-48-4 CAPLUS
CN Glycine, (2R)-N-[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methyl-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy]acetyl]-2-phenylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-49-5 CAPLUS
CN Butanoic acid, 2-[[(2R)-[[[(3,3-dibutyl-2,3,4,5-tetrahydro-7-methyl-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino](4-hydroxyphenyl)acetyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-50-8 CAPLUS
CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-(2S)-2-aminobutanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-51-9 CAPLUS
CN L-Proline, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-52-0 CAPLUS
CN 2-Azetidinecarboxylic acid, 1-[(2R)-[[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]phenylacetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-53-1 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-54-2 CAPLUS
CN D-Leucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-55-3 CAPLUS
CN L-Leucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-56-4 CAPLUS
CN D-Leucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-57-5 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-3-(trimethylsilyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-58-6 CAPLUS
CN D-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-3-(trimethylsilyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-90-6 CAPLUS
CN L-Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501692-96-2 CAPLUS
CN L-Serine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501693-06-7 CAPLUS
CN D-Leucine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-4-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501693-07-8 CAPLUS
CN Alanine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]-2-(4-hydroxyphenyl)glycyl-3-(trimethylsilyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l2; d l5; d his; log y
L2 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

L5 HAS NO ANSWERS
L4 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.
L5 QUE ABB=ON PLU=ON L4

(FILE 'HOME' ENTERED AT 19:03:55 ON 01 JUN 2006)

FILE 'REGISTRY' ENTERED AT 19:04:03 ON 01 JUN 2006
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 4 S L2
L4 STRUCTURE UPLOADED
L5 QUE L4
L6 88 S L2 FUL
L7 0 S L5 FUL

FILE 'CAPLUS' ENTERED AT 19:05:20 ON 01 JUN 2006
L8 6 S L6

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.58	365.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.50	-4.50

STN INTERNATIONAL LOGOFF AT 19:06:24 ON 01 JUN 2006